Adaptive clinical trial designs for phase I cancer studies
From MaRDI portal
Publication:2452091
DOI10.1214/14-SS106zbMath1333.62286OpenAlexW1975592428MaRDI QIDQ2452091
Weng Kee Wong, Oleksandr Sverdlov, Yevgen Ryeznik
Publication date: 30 May 2014
Published in: Statistics Surveys (Search for Journal in Brave)
Full work available at URL: https://projecteuclid.org/euclid.ssu/1401369114
stochastic approximationethicsestimation efficiencymaximum tolerated doseoptimal designsphase Iup-and-down designscontinual reassessment methodBayesian designstoxicity``best intention designsdose finding studiesoncology trial designs
Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50) Stochastic approximation (62L20) Sequential statistical design (62L05) Sequential statistical analysis (62L10)
Related Items
A new design of the continual reassessment method ⋮ Performance Measures in Dose‐Finding Experiments ⋮ A continual reassessment method without undue risk of toxicity ⋮ On optimal designs for clinical trials: an updated review
Uses Software
Cites Work
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- A note on the robustness of the continual reassessment method
- Adaptive Bayesian compound designs for dose finding studies
- Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control
- The treatment versus experimentation dilemma in dose finding studies
- Existence of three solutions to a second-order nonhomogeneous multipoint boundary-value problem
- Approximate policy optimization and adaptive control in regression models
- Stochastic approximation and modern model-based designs for dose-finding clinical trials
- Continual reassessment and related dose-finding designs
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- Bayesian models and decision algorithms for complex early phase clinical trials
- Approximate dynamic programming and its applications to the design of Phase I cancer trials
- Design efficiency in dose finding studies
- Convergence properties of sequential Bayesian \(D\)-optimal designs
- Unifying CRM and EWOC designs for phase I cancer clinical trials
- Randomized group up and down experiments
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Operating characteristics of the standard phase I clinical trial design.
- Properties of frequency distributions induced by general up-and-down methods for estimating quantiles
- Asymptotic normality of maximum likelihood estimators from multiparameter response-driven designs
- Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
- Number of patients per cohort and sample size considerations using dose escalation with overdose control
- A new look at evaluating MTD designs in cancer research
- Cumulative cohort design for dose-finding
- Up-and-down experiments of first and second order
- Group up-and-down designs for dose-finding
- Theoretical study of the continual reassessment method
- Adaptive designs for dose-finding based on efficacy-toxicity response
- Bayesian dose finding for combined drugs with discrete and continuous doses
- Optimal Design for Nonlinear Response Models
- A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients
- Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes
- Continual Reassessment Method for Partial Ordering
- Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs
- A class of designs for Phase I cancer clinical trials combining Bayesian and likelihood approaches
- A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents
- Dose-Finding Based on Feasibility and Toxicity in T-cell Infusion Trials
- Dose-Finding Designs for HIV Studies
- Dose Finding Using the Biased Coin Up-and-Down Design and Isotonic Regression
- On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance
- Curve-Free and Model-Based Continual Reassessment Method Designs
- A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method
- Continual Reassessment Method for Ordered Groups
- Dose-Finding with Two Agents in Phase I Oncology Trials
- Bayesian Optimal Designs for Phase I Clinical Trials
- Robust EM Continual Reassessment Method in Oncology Dose Finding
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
- Sequential Designs in Bioassay
- Design and Analysis of Phase I Clinical Trials
- Statistical Methods for Dose‐Finding Experiments
- A New Dose‐Finding Design for Bivariate Outcomes
- Designs for Single- or Multiple-Agent Phase I Trials
- Monitoring late-onset toxicities in phase I trials using predicted risks
- Coherence principles in dose-finding studies
- Sequential Implementation of Stepwise Procedures for Identifying the Maximum Tolerated Dose
- Derivation of Exact Distributions Following an Up-and-Down Design
- Efficient Sequential Designs With Binary Data
- Consistency of continual reassessment method under model misspecification
- Miscellanea. A stopping rule for the continual reassessment method
- TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
- Continual Reassessment Method: A Likelihood Approach
- A Random Walk Rule for Phase I Clinical Trials
- THE DISTRIBUTION OF THE MAXIMUM LIKELIHOOD ESTIMATOR IN UP-AND-DOWN EXPERIMENTS FOR QUANTAL DOSE-RESPONSE DATA
- Bayesian decision procedures based on logistic regression models for dose-finding studies
- Designs foe phase i cancer clinical trials with differentiation of graded toxicity
- A Curve‐Free Method for Phase I Clinical Trials
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- Estimating the Probability of Toxicity at the Recommended Dose Following a Phase I Clinical Trial in Cancer
- Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design
- Small-Sample Confidence Sets for the MTD in a Phase I Clinical Trial
- Toxicity in sequential dose-response experiments
- Sequential Designs for Dose Escalation Studies in Oncology
- A Semiparametric Sequential Algorithm for Estimation of Dose–Response Curve
- Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
- Stochastic approximation with virtual observations for dose-finding on discrete levels
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
- Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials
- Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
- Übersichtsarbeiten
- Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
- Non-parametric optimal design in dose finding studies
- Continual reassessment designs with early termination
- Two‐Dimensional Dose Finding in Discrete Dose Space
- Retrospective Analysis of Sequential Dose‐Finding Designs
- A Method for Obtaining and Analyzing Sensitivity Data
- A Stochastic Approximation Method
